Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Analysis
  4. Volume 20, Issue 8
  5. Article
Volume 20, Issue 8
  • ISSN: 1573-4129
  • E-ISSN: 1875-676X

Abstract

Background

N-nitrosamines have recently been discovered in metformin hydrochloride and other generic drugs. To quantify the five N-nitrosamines in metformin hydrochloride, we devised sensitive and reliable multiple reactions monitoring mode-based GC-MS/MS technique, particularly, N-nitrosodiethy amine (NDEA), N-nitroso ethyl isopropylamine (NEIPA), N-nitrosodiisopropylamine (NDIPA), N-nitrosodipropylamine (NDPA), as well as N-nitrosodibutylamine (NDBA).

Objective

To develop a sensitive, precise, and accurate MRM mode based GC-MS/MS method for the quantification of five N-nitrosamines in metformin hydrochloride and valídate as per ICH guidelines.

Methods

The settings for mass spectrometry and gas chromatography were optimized. With the linearity, sensitivity, specificity, accuracy, and precision of the parameter, the procedure was as per the recommendation of ICH: International Council for Harmonization guidelines.

Results

N-nitrosamines in metformin hydrochloride had detection and quantification limits of 0.001 ppm and 0.004 ppm, correspondingly. The obtained results were within the sensitivity limitations issued by the US Food and Drug Administration. The calibration curve's regression coefficients for five N-nitrosamines were over 0.99, demonstrating the process's good linearity. The retrievals of N-nitrosamines in metformin hydrochloride between 97.1 – 127.4%. The RSD (Relative Standard Deviation) was lower than 10% for both inter-day and intra-day precision studies.

Conclusion

The proposed method exhibited a rapid analysis capability, high accuracy, sensitivity, and precision, making it a trustworthy method for monitoring N-nitrosamines in metformin hydrochloride.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpa/10.2174/0115734129332940240919113159
2024-10-18
2025-06-21

  • From This Site

    /content/journals/cpa/10.2174/0115734129332940240919113159
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SzekelyG. Amores de SousaM.C. GilM. Castelo FerreiraF. HeggieW. Genotoxic impurities in pharmaceutical manufacturing: sources, regulations, and mitigation.Chem. Rev.2015115168182822910.1021/cr300095f26252800
     [Google Scholar]
  2. RamanN.V.V.S.S. PrasadA.V.S.S. Ratnakar ReddyK. Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspective.J. Pharm. Biomed. Anal.201155466266710.1016/j.jpba.2010.11.03921193280
     [Google Scholar]
  3. TeasdaleA. ElderD.P. Analytical control strategies for mutagenic impurities: Current challenges and future opportunities.Trends Analyt. Chem.2014103228
     [Google Scholar]
  4. RojasL.B.A. GomesM.B. Metformin: An old but still the best treatment for type 2 diabetes.Diabetol. Metab. Syndr.201351610.1186/1758‑5996‑5‑623415113
     [Google Scholar]
  5. NasriH. Rafieian-KopaeiM. Metformin: Current knowledge.J. Res. Med. Sci.201419765866425364368
     [Google Scholar]
  6. UmapathiP. AyyappanJ. QuineS.D. Quantitative determination of metformin hydrochloride in tablet formulation containing croscarmellose sodium as disintegrant by HPLC and UV spectrophotometry.Trop. J. Pharm. Res.201211110711610.4314/tjpr.v11i1.14
     [Google Scholar]
  7. HassanS.S.M. MahmoudW.H. ElmosallamyM.A.F. OthmanA.H.M. Determination of metformin in pharmaceutical preparations using potentiometry, spectrofluorimetry and UV–visible spectrophotometry.Anal. Chim. Acta19993781-329931110.1016/S0003‑2670(98)00500‑5
     [Google Scholar]
  8. HamdanI.I. JaberA.K.B. AbushoffaA.M. Development and validation of a stability indicating capillary electrophoresis method for the determination of metformin hydrochloride in tablets.J. Pharm. Biomed. Anal.20105351254125710.1016/j.jpba.2010.03.01720395106
     [Google Scholar]
  9. LakshmiK. RajeshT. SharmaS. Simultaneous determination of Metformin and pioglitazone by reversed phase HPLC in pharmaceutical dosage forms.Int. J. Pharm. Pharm. Sci.20091162166
     [Google Scholar]
  10. KolteB.L. RautB.B. DeoA.A. BagoolM.A. ShindeD.B. Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form.J. Chromatogr. Sci.2004421273114965412
     [Google Scholar]
  11. MohamedA.M.I. MohamedF.A.F. AhmedS. MohamedY.A.S. An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2015997162210.1016/j.jchromb.2015.05.03226079265
     [Google Scholar]
  12. SharmaR. ChaturvediS.C. SahooP.K. Simultaneous estimation of metformin hydrochloride and pioglitazone hydrochloride by RPHPLC method from combined tablet dosage form.Indian J. Pharm. Sci.200870338338610.4103/0250‑474X.4301020046754
     [Google Scholar]
  13. VaingankarP.N. AminP.D. Development and Validation of Stability-Indicating RP-HPLC Method for Simultaneous Determination of Metformin HCl and Glimepiride in Fixed-Dose Combination.Anal Chem Insights201611132010.4137/ACI.S38137
     [Google Scholar]
  14. MarieA.A. HammadS.F. SalimM.M. ElkhodaryM.M. KamalA.H. Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride.Sci. Rep.2023131433410.1038/s41598‑023‑30051‑x36928591
     [Google Scholar]
  15. TH.K. DG.S. RP-HPLC method for simultaneous estimation of Metformin Hydrochloride and Canagliflozin in pharmaceutical formulation.Indian Drugs2021586495910.53879/id.58.06.10607
     [Google Scholar]
  16. EMA update on metformin diabetes medicines.Available from: https://www.ema.europa.eu/en/news/ema-update-metformin-diabetes-medicines 2019
  17. Technical Fact Sheet—N Nitrosodimethylamine (NDMA).Available from: http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://nepis.epa.gov/Exe/ZyNET.exe/P100LTGG.TXT?ZyActionD=ZyDocument&Client=EPA&Index=2011+Thru+2015&Docs=&Query=&Time=&EndTime=&SearchMethod=1&TocRestrict=n&Toc=&TocEntry=&QField=&QFieldYear=&QFieldMonth=&QFieldDay=&IntQFieldOp=0&ExtQFieldOp=0&XmlQuery=&File=D%3A%5Czyfiles%5CIndex%20Data%5C11thru15%5CTxt%5C00000014%5CP100LTGG.txt&User=ANONYMOUS&Password=anonymous&SortMethod=h%7C-&MaximumDocuments=1&FuzzyDegree=0&ImageQuality=r75g8/r75g8/x150y150g16/i425&Display=hpfr&DefSeekPage=x&SearchBack=ZyActionL&Back=ZyActionS&BackDesc=Results%20page&MaximumPages=1&ZyEntry=1&SeekPage=x&ZyPURL 2014
  18. BrendlerS.Y. TompaA. HutterK.F. PreussmannR. Pool-ZobelB.L. In vivo and in vitro genotoxicity of several N -nitrosamines in extrahepatic tissues of the rat.Carcinogenesis199213122435244110.1093/carcin/13.12.24351473254
     [Google Scholar]
  19. VecchiaC.L. DʼAvanzoB. AiroldiL. BragaC. DecarliA. Nitrosamine intake and gastric cancer risk.Eur. J. Cancer Prev.19954646947410.1097/00008469‑199512000‑000058580782
     [Google Scholar]
  20. YangJ. MarzanT.A. YeW. SommersC.D. RodriguezJ.D. KeireD.A. Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin.AAPS J.20202248910.1208/s12248‑020‑00473‑w32613429
     [Google Scholar]
  21. TummalaS.R. AmgothK.P. Development of GC-MS/MS Method for Simultaneous Estimation of Four Nitrosoamine Genotoxic Impurities in Valsartan.Turk. J. Pharm. Sci.202219445546110.4274/tjps.galenos.2021.1770236047600
     [Google Scholar]
  22. ZmysłowskiA. KsiążekI. SzterkA. N-Nitrosodimethylamine Contamination in the Metformin Finished Products.Molecules20202522530410.3390/molecules2522530433202951
     [Google Scholar]
  23. YükselB. ŞenN. Development and validation of a GC-FID method for determination of cocaine in illicit drug samples.Marmara Pharm. J.2018224511518
     [Google Scholar]
  24. ÖncüT. YükselB. BinayE. ŞenN. LC-MS/MS Investigation of nitrosamine impurities in certain Sartan group medicinal products available in Istanbul, Türkiye.Ann. Pharm. Fr.2024821728310.1016/j.pharma.2023.08.00237567559
     [Google Scholar]
  25. ICH Harmonised Tripartite Guideline.Q2(R1): Validation of analytical procedures: Text and methodology.Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf 2005
  26. DasguptaS. DhyaniV. VyasS. ChurleyM. Quantification of Nitrosamine Impurities in Metformin Using Agilent GC/MS/MS Instrumentation.2020Available from: https://www.agilent.com/cs/library/applications/application-nitrosamine-metformin-gc-ms-ms-5994-2419en-agilent.pdf
/content/journals/cpa/10.2174/0115734129332940240919113159
Loading
Head Space GC-MS/MS Method for Quantification of Five Nitrosoamine-Genotoxic Impurities in Metformin HCl
Current Pharmaceutical Analysis 20, 944 (2024); https://doi.org/10.2174/0115734129332940240919113159
/content/journals/cpa/10.2174/0115734129332940240919113159
/content/journals/cpa/10.2174/0115734129332940240919113159
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): GC-MS/MS; Metformin hydrochloride; N-nitroso ethyl isopropylamine (NEIPA); N-nitrosodibutylamine (NDBA). genotoxic impurity; N-nitrosodiethy amine (NDEA); N-nitrosodiisopropylamine (NDIPA); N-nitrosodipropylamine (NDPA)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test